ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Elanco Animal Health Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.49−0.06 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $11.88B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
55.0%+6.0 pts over 5 years
Net margin
-4.9%+12.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.2% | +2.2% | +7.6% | – | |
| Gross profit | +6.4% | +1.3% | +10.1% | – | |
| Free cash flow | -27.9% | +0.4% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -0.7% | -8.2% | -3.7% | |
| Return on assets | – | -4.3% | -1.8% | |
| Current ratio | – | 1.65 | 2.17 | |
| Debt to equity | – | 0.72 | 0.61 | |
| Inventory turnover | – | 1.3× | 1.3× | |
| Capex to revenue | 3.8% | 4.1% | 5.9% | |
| Diluted shares | 293M | 441M | 496M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Elanco Animal Health generated $2.31B from operations and spent $893.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.31B
Used
$893.00M
Capital expenditure$893.00M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.9%
×Asset turnover0.36×
×Equity multiplier2.05×
=Return on equity, FY2025-3.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.9% | 0.36× | 2.05× | -3.7% |
| FY2024 | 7.6% | 0.33× | 2.19× | 5.5% |
| FY2023 | -27.9% | 0.30× | 2.21× | -18.2% |
| FY2022 | -1.8% | 0.28× | 2.16× | -1.1% |
| FY2021 | -10.1% | 0.28× | 2.14× | -6.1% |
| FY2020 | -17.5% | 0.25× | 1.91× | -8.2% |
| FY2019 | 2.2% | 0.34× | 1.67× | 1.3% |
| FY2018 | 2.8% | 0.34× | 1.38× | 1.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$232.00M
- Cash generatingOperating cash flow above zero$560.00M
- Return on assets improvedROA up on the prior year2.4% → -1.8%
- Earnings backed by cashOperating cash flow above net income$560.00M vs -$232.00M
- Less leverageLong-term debt to assets fell33.9% → 29.5%
- Better liquidityCurrent ratio rose2.44 → 2.17
- No dilutionShare count did not rise497M → 496M
- Gross margin improvedGross margin up on the prior year54.88% → 54.99%
- More efficientAsset turnover rose0.31 → 0.37